Method: Use siRNA or CRISPR-generated GGCT2;1 knockout lines as negative controls. For plants (e.g., Arabidopsis), immunoblotting with root or leaf lysates from wild-type vs. ggct2;1 mutants should show a ~25 kDa band absence in mutants . In mammalian cancer cells (e.g., PC3 prostate cancer), validate via siRNA-mediated GGCT knockdown and monitor c-Met/pRB expression changes .
Pitfall: Cross-reactivity with GGCT2;2/2;3 isoforms. Include isoform-specific knockout controls.
Optimization:
Application: Pair with HPLC-based GSH quantification. Example workflow:
Data conflict analysis:
Resolution: Use tissue-specific promoters (e.g., ROOT-SPECIFIC vs. CANCER-ASSOCIATED) to isolate context-dependent roles.
Approach:
Hypothesis: GGCT2;1 modulates T-cell exhaustion via GSH-regulated PD-1 internalization.
Experimental pipeline: